These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17895878)

  • 1. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

  • 2. [What does "PSA recurrence mean? "Active surveillance" for all risk groups is an option].
    Hautmann R
    Urologe A; 2006 Oct; 45(10):1239. PubMed ID: 17006696
    [No Abstract]   [Full Text] [Related]  

  • 3. PSA velocity and prostate cancer.
    Bianco FJ; Kattan MW; Scardino PT
    N Engl J Med; 2004 Oct; 351(17):1800-2; author reply 1800-2. PubMed ID: 15499669
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 5. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer with low PSA levels.
    Datta MW; Berman JJ; Dhir R
    N Engl J Med; 2004 Oct; 351(17):1802-3. PubMed ID: 15499672
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 12. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of PSA doubling time to monitor prostate cancer recurrence.
    Wieder JA; Belldegrun AS
    Mayo Clin Proc; 2001 Jun; 76(6):571-2. PubMed ID: 11393493
    [No Abstract]   [Full Text] [Related]  

  • 14. Surgical management of high risk prostate cancer: the Mayo Clinic experience.
    Boorjian SA; Blute ML
    Urol Oncol; 2008; 26(5):530-2. PubMed ID: 18774468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
    BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PSA kinetics after total prostatectomy].
    Riedinger JM; Eche N; Fulla Y; Thuillier F
    Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
    Stephenson AJ
    Urology; 2008 Sep; 72(3):719-20. PubMed ID: 18762055
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
    DuBois RN
    J Clin Oncol; 2006 Jun; 24(18):2691-3. PubMed ID: 16782907
    [No Abstract]   [Full Text] [Related]  

  • 19. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.